Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Primary retroperitoneal seminoma

S J Buskirk, R G Evans, G M Farrow

    Cancer
    |May 1, 1982
    PubMed
    Summary
    This summary is machine-generated.

    Retroperitoneal seminomas, rare cancers without testicular involvement, were reviewed. Radiation therapy showed promise, with survival influenced by tumor characteristics and disease stage.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Carcinoma in Situ of the Bladder.

    Cancer·2018
    Same author

    Long-term follow-up of radiotherapy for prostate cancer.

    International journal of radiation oncology, biology, physics·2004
    Same author

    Long-term follow-up of radical retropubic prostatectomy for prostate cancer.

    European urology·2002
    Same author

    The consequences of treatment and disease in patients with primary CNS non-Hodgkin's lymphoma: cognitive function and performance status. North Central Cancer Treatment Group.

    Neuro-oncology·2001
    Same author

    A prospective, randomized, double-blind, placebo-controlled study of orbital radiotherapy for Graves' ophthalmopathy.

    Ophthalmology·2001
    Same author

    The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, II: characteristics of patients enrolled and not enrolled. COMS Report No. 17.

    Archives of ophthalmology (Chicago, Ill. : 1960)·2001
    Same journal

    Sexual orientation and gender identity based disparities in colorectal, cervical, and breast cancer screening in the United States.

    Cancer·2026
    Same journal

    Toward exercise as standard care for older cancer survivors.

    Cancer·2026
    Same journal

    Maintenance therapy in gynecologic malignancies: Current and future state.

    Cancer·2026
    Same journal

    Long-term outcomes of evolving treatment regimens in Ewing sarcoma survivors diagnosed 1970-1999: A report from the Childhood Cancer Survivor Study.

    Cancer·2026
    Same journal

    Large-scale osteosarcoma sequencing reveals age-associated genomic architectures.

    Cancer·2026
    Same journal

    EZH2 inhibitor tazemetostat voluntarily withdrawn from market.

    Cancer·2026
    See all related articles

    Area of Science:

    • Oncology
    • Urology

    Background:

    • Seminomas are germ cell tumors originating from the testes.
    • Retroperitoneal seminomas, occurring outside the testes, are exceptionally rare.

    Purpose of the Study:

    • To analyze the clinical characteristics, treatment, and outcomes of patients with retroperitoneal seminoma.
    • To identify prognostic factors for retroperitoneal seminoma.

    Main Methods:

    • Retrospective review of 12 cases of retroperitoneal seminoma diagnosed between 1950 and 1975 at the Mayo Clinic.
    • Analysis of patient demographics, tumor characteristics, treatment modalities (primarily radiation therapy), and survival data.

    Main Results:

    • Seven of eleven patients treated with radiation therapy survived with a median follow-up of six years.

    Related Experiment Videos

  • Median survival for the five deceased patients was ten months.
  • Prognostic factors included typical histopathology, encapsulated tumors, and absence of symptoms or kidney dysfunction as favorable indicators.

    • Conclusions:

    • Radiation therapy is a viable treatment for retroperitoneal seminoma.
    • Treatment recommendations include irradiation of the tumor bed and para-aortic lymph nodes to at least 2,000 rads.
    • Prophylactic treatment of mediastinal and supraclavicular lymph nodes may be considered in cases with poor prognostic factors.